



PREVENTING UNNECESSARY NECK SURGERY ON PATIENTS WITH ORAL CAVITY CANCER

Company Name: AMENDIS LTD.

Country of Registration: Israel.

Key Stake Holders: Goldman Bio; Shamir Kaminsky; Tarel Holdings Ltd. ; Hadasit Medical Research Services and Development.

Fields of Activity: Life Sciences/Oncology


Investment Opportunity:

Website	www.amendis.co.il
Included in the prospectus of Goldman Bio Limited Partnership	✓
Estimated Valuation (External, July 2020)	USD 9.3 Million
Planned Investment Multiple	8
Planned ROI	2 Years
Estimated Risk	Low-Medium
LinkedIn	www.linkedin.com/company/amendis1

The Product: A genomic measurement diagnostic test based on AI to avoid unnecessary neck surgeries on patients with oral cavity cancer.

Business Opportunity: The Global Cancer Diagnostics Market size was valued at USD 144.4 billion in 2018 and is expected to register a CAGR of 7.0% over the forecast period (2019-2026). From the beginning of 2019 until mid-June 2020, there have been 97 successful IPOs from the biotech sector on the Nasdaq, out of a total of 254 IPOs (approximately 38%). A company in the same field as Amendis went public (IPO) in July 2019, and its shares are currently trading at 2.4 times their issue price.

According to studies, the global diagnostics market for head and neck cancer totaled about \$ 1,242 Million in 2018, and is expected to be around \$ 2,755 Million by 2025. Accordingly, the CAGR for 2019-2027 is expected to be around 12%. According to research by Technavio, the market is expected to grow thanks to the growing popularity of autoimmune treatments for head and neck cancer. Private companies and government organizations run ventures to prevent and monitor cancer, by encouraging awareness and early detection of the disease. These ventures are also expected to support market growth. The main competitors in this market are: General Electric Co., Canon Inc., Karl Storz SE & CO. KG, Apteryx Imaging Inc., and Accuray Inc.



The Need: Worldwide, head and neck cancers are the sixth leading cancer group by incidence, with approximately 650,000 new patients diagnosed annually, resulting in more than 350,000 deaths every year. Cervical lymph node metastasis is the single most important prognostic factor in oral cancer: survival chances are reduced by 50% when compared to those with similar primary tumors without neck metastases. Following biopsy, a surgeon is nowadays compelled to perform an elective neck dissection when the depth of the tumor is more than 3mm.



However, around 70% of these surgeries turn out to be unnecessary, as the tumor remains local. Neck dissections are subject to numerous potential operative complications that are common to all operative procedures, as well as complications specific to this procedure. These surgeries are costly, and highly affect the patients' quality of life in the following years.



The Solution: Amendis provides a scientific proven analytic diagnostic test to aid the physician in avoiding unnecessary neck surgeries. Amendis's unique AI-based genomic measurement test has the ability to predict the development of head and neck metastasis (the spread of the malignant growth) immediately following the primary diagnosis of tumors in the oral cavity, thus preventing unnecessary neck surgeries. The test screens tissue obtained from the patients' biopsy. Experimental results have shown statistical significance in line with or higher than industry standards.

The technology is based on wide research performed by Dr. Yoav Smith, formerly the Head of the Genomic Data Analysis Unit at the Hebrew University of Jerusalem.

Status:

- **Present Status:** Algorithm and AI System Development.
- **Forthcoming Milestones:** Clinical trials and regulatory approval, commencement of sales.
- **IP:** Medical Imaging Method and System US8,467,583 – Granted.
Methods of Diagnosing Cancer Using Cancer Testis Antigens (PCT/IL2017/050575).
License Agreement with Yissum Technology Company of the Hebrew University.
License Agreement with Hadasit Medical Research & Development.

Business Model:

- **Sales Strategy:** Sales planned through distributors, medical insurance companies and health maintenance organizations.
- **Exit:** IPO/M&A.

The Team:



Dr. Amit Cohen Ph.D R.D, Co-CEO

A molecular biologist with an expertise in the field of RNA, a registered dietitian. His research has focused on the role of microRNA in the development of cancer.

Since 2012 Dr. Cohen has been analyzing cancer gene expression data in collaboration with Dr. Yoav Smith from the Hebrew University of Jerusalem.



Dr. Yoav Smith, CTO;

A graduate of the Technion (BSEE), University of Pittsburgh (MSEE) and a PhD from the Hebrew University Medical School, former head of Genomic Data Analysis Unit at the Hebrew University. Dr. Smith have published more than 50 papers, 8 patents and is a senior lecturer in the field data visualization and analysis.



Dr. Nir Hirshorn, Medical Director;

Dr. Hirshoren is a Senior Physician and Oncological Surgeon in the Department of Ear Nose & Throat, and Head & Neck Surgery at the Hadassah Medical Center, Jerusalem.



Mr. Shamir Kaminsky, Specialist in public health

An entrepreneur in the Biomedical Field, former CEO of Leumit Health Fund and an expert in Israel's medical insurance system, highly experienced in international marketing.

